Treatment Patterns and Clinical Outcomes among Advanced NSCLC Patients with EGFR exon 20 Insertion Mutations in China

被引：0
|
作者：
Wang, Y. [1 ]
Lin, H. M. [2 ]
Ning, N. [3 ]
Du, F. [4 ]
Gao, X. [3 ]
Dong, Q. [2 ]
Yang, G. [1 ]
Xu, H. [5 ]
He, Y. [6 ]
Zhou, C. [6 ]
机构：
[1] Natl Clin Res Ctr Canc, Canc Hosp, Natl Canc Ctr, Dept Med Oncol, Beijing, Peoples R China
[2] Takeda Dev Ctr Amer Inc, Lexington, MA USA
[3] OPEN Hlth, Bernardsville, NJ USA
[4] OPEN Hlth, Shanghai, Peoples R China
[5] Chinese Acad Med Sci & Peking Uni, Canc Hosp, Natl Clin Res Ctr Canc, Dept Comprehens Oncol,Natl Canc Ctr, Beijing, Peoples R China
[6] Shanghai Pulm Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Non-small cell lung cancer in China; Treatment patterns; Clinical outcomes;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP10.01-17
引用
收藏
页码：S609 / S609
页数：1
相关论文
共 50 条
  • [41] EGFR Exon 20 Insertion Mutations in NSCLC: The Need for Accurate Naming Conventions and Implications for Personalized Therapy
    Park, J.
    Song, J. -Y.
    Sung, M.
    Kwon, M. J.
    Kim, C. R.
    Shin, Y. K.
    Choi, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S484 - S484
  • [42] Short-term efficacy of furmonertinib in treatment of NSCLC patients with EGFR exon20 insertion.
    Zhou, Xiaoyue
    Dong, Huajie
    Li, Peng
    Wu, Changling
    Lu, Hongjun
    Xiao, Mingzhe
    Zhou, Tong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions
    Liao, Ying-Ting
    Wang, Lei-Chi
    Sun, Ruei-Lin
    Yeh, Yi-Chen
    Huang, Hsu-Ching
    Shen, Chia-, I
    Tseng, Yen-Han
    Hsiao, Tsu-Hui
    Chao, Heng-Sheng
    Luo, Yung-Hung
    Chen, Yuh-Min
    Chiang, Chi-Lu
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (12) : 10365 - 10376
  • [44] CLINICAL, STRUCTURAL AND BIOCHEMICAL CHARACTERIZATION OF EGFR EXON 20 INSERTION MUTATIONS IN LUNG CANCER
    Costa, Daniel B.
    Yasuda, Hiroyuki
    Park, Eunyoung
    Yun, Cai-Hong
    Huberman, Mark S.
    Oxnard, Geoffrey R.
    Sequist, Lecia V.
    Riely, Gregory
    Soo, Ross
    Eck, Michael J.
    Kobayashi, Susumu S.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S355 - S355
  • [45] Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions
    Ying-Ting Liao
    Lei-Chi Wang
    Ruei-Lin Sun
    Yi-Chen Yeh
    Hsu-Ching Huang
    Chia-I Shen
    Yen-Han Tseng
    Tsu-Hui Hsiao
    Heng-Sheng Chao
    Yung-Hung Luo
    Yuh-Min Chen
    Chi-Lu Chiang
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 10365 - 10376
  • [46] EGFR mutations in patients with advanced NSCLC
    Fiala, Ondrej
    Pesek, Milos
    Finek, Jindrich
    Bruha, Frantisek
    Bortlicek, Zbynek
    Krejci, Jana
    Benesova, Lucie
    Minarik, Marek
    LUNG CANCER, 2012, 77 : S30 - S30
  • [47] EGFR exon 20 insertion mutation in advanced thymic squamous cell carcinoma: Response to apatinib and clinical outcomes
    Su Yudong
    Meng Zhaoting
    Wang Xinyue
    Lin Li
    Xu Xiaoyan
    Zuo Ran
    Chen Jinliang
    Chen Peng
    THORACIC CANCER, 2018, 9 (07) : 885 - 891
  • [48] Extensive functional evaluation of exon 20 insertion mutations of EGFR
    Hirose, Takeshi
    Ikegami, Masachika
    Endo, Makoto
    Matsumoto, Yoshihiro
    Nakashima, Yasuharu
    Mano, Hiroyuki
    Kohsaka, Shinji
    LUNG CANCER, 2021, 152 : 135 - 142
  • [49] Approval for RYBREVANT® (Amivantamab) in advanced NSCLC and activating EGFR Exon 20 Insertion Mutations after Failure of Platinum-based Therapy
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (1-2) : 72 - 72
  • [50] A comparison of real-world incidence of EGFR exon 20 insertion mutations among patients with NSCLC in five Asian markets, stratified by testing methodology
    De Richter, Pieter
    Koo, Mei Yee
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345